Arthritis drug shown to reduce risk of COVID death
By Reuters
(Reuters) – Eli Lilly and
Incyte’s arthritis drug baricitinib
helped reduce the risk of
death in hospitalised COVID-19
patients by 13% regardless of
which other coronavirus treatment
they were given, according
to a large British study.
Over 8,000 patients were
administered baricitinib in addition
to usual care, at random,
or usual care alone, as part of
the so-called RECOVERY trial,
scientists from the University of
Oxford said on Thursday.
Results showed 546 patients
in the usual care group died
within 28 days but only 513
patients in the baricitinib group
died where they were also given
a corticosteroid like dexamethasone,
tocilizumab or remdesivir.
“This result confirms and
extends earlier findings, providing
greater certainty that
baricitinib is beneficial and
new data to guide the treatment
of COVID-19 patients
with a combination of drugs to
dampen the immune response,”
said Peter Horby, Oxford professor
and joint chief investigator.
The findings are consistent
with the U.S. drugmakers’ own
research from a smaller trial
last August and comes after
a World Health Organization
panel had earlier this year
recommended baricitinib for
patients with severe COVID-19
in combination with corticosteroids.
Baricitinib belongs to a class
of drugs called Janus Kinase
(JAK) inhibitors which work by
blocking actions of enzymes that
play a role in the immune system
processes and lead to inflammation,
› WELCOME MTA, VERIZON, PORT AUTHORITY EMPLOYEES ‹
A Natural Approach To Living
Healthy & Pain Free
• Back Pain • Foot Pain • Headaches • Diabetes
• Sleep • Arthritis • Neck Pain • Shoulder Pain
• Scoliosis • Fibromayalgia • Balance • Hormones
Effective in
Treating Allergies,
ADHD. Asthma ,
Digestive issues
LIVE HOLISTIC
DR. VINCENT
ADAMO
FOR APPOINTMENT CALL
718-921-5483
Caribbean L 16 ife, MARCH 4-10, 2022
often seen in severe COVID-
19 as lung damage.
U.S. authorities have
approved the emergency use
of baricitinib, sold under the
brand name Olumiant, with or
without taking Gilead’s antiviral
remdesivir, while European
regulators are reviewing the
treatment for approval.
In the RECOVERY trial,
baricitinib also increased the
chances of patients being discharged
alive within 28 days
and reduced the risk of their
condition worsening, scientists
A woman walks past a sign amidst the spread of the coronavirus disease (COVID-19), in
London, Britain, Jan. 24, 2022. REUTERS/Hannah McKay/File
said.
Scientists behind the
RECOVERY trial had shown
dexamethasone saved the lives
of COVID-19 patients, in what
was called a “major breakthrough”
in the pandemic, and
also found tocilizumab worked
against coronavirus.
(Reporting by Pushkala Aripaka
in Bengaluru; Editing by
Krishna Chandra Eluri)
GET BACK ON TRACK FOR 2022
HOURS:
Mon. Wed. 9am-12pm
3pm-6:30pm
Tues. Thurs. Fri. 1pm - 6:30pm
Kids
Chiropractic
Care Available
Chiropractic & Holistic Care
446 Bay Ridge Parkway, Brooklyn, NY 11209
/vicentadamo • www.liveholistic.net
Rogosin is the largest not-for-profit dialysis provider in NYC
with locations in Brooklyn, Queens, Manhattan and the Bronx.
Call 888-ROGOSIN
(888-764-6746)
Our dialysis centers offer:
All forms of home dialysis
training
Support for patients in all
areas of their lives
A physician and/or nurse
practitioner to see patients at
every treatment
Comfortable treatment rooms
with cable TV
Rogosin Dialysis Centers: Queens
Rogosin Queens Auburndale
39-20 Utopia Parkway
Rogosin Queens Woodside
66-20 Queens Boulevard
www.rogosin.org
Health
/www.liveholistic.net
/www.rogosin.org
/www.liveholistic.net
/www.rogosin.org
